
Gradient Denervation Technologies Announces Acceptance Into FDA's Total Product Life Cycle Advisory Program For Development Of Its Pulmonary Artery Denervation System
The FDA's Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient's Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations.
The Gradient Denervation System is a novel technology intended to treat patients with Group 2 pulmonary hypertension due to left-sided heart disease. Treatment is accomplished by ablating nerves around the pulmonary artery using therapeutic ultrasound energy in a minimally invasive, percutaneous procedure. The straightforward catheter platform was designed specifically for the pulmonary artery anatomy and leverages known interventional techniques. The treatment goal is to down-regulate the sympathetic activity in the pulmonary vascular tree to reduce vascular resistance and decrease pulmonary pressures.
“We're excited to be included in the TAP Pilot as the program will help streamline collaboration with FDA – from initiating our pivotal clinical study to accelerating access to this breakthrough therapy upon approval,” said Martin Grasse, Chief Executive Officer at Gradient Denervation Technologies.“There are no approved drug or device therapies in the United States for this group of pulmonary hypertension patients, which reinforces the need to expedite access to new innovative therapies. We expect that guidance from TAP Pilot advisors will be immensely valuable in developing a targeted therapy intended to improve outcomes and quality of life for these underserved patients.”
About Gradient Denervation Technologies
Gradient Denervation Technologies is a Paris-based medical device company developing a minimally invasive, ultrasound-based device for the treatment of pulmonary hypertension. Gradient leverages intellectual property developed at Stanford University. The Gradient Denervation System is for investigational use only and is not approved for commercial use.
For more information, please visit: .
CONTACT: Media Contact ...

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Thinkmarkets Adds Synthetic Indices To Its Product Offering
- Ethereum Startup Agoralend Opens Fresh Fundraise After Oversubscribed $300,000 Round.
- KOR Closes Series B Funding To Accelerate Global Growth
- Wise Wolves Corporation Launches Unified Brand To Power The Next Era Of Cross-Border Finance
- Lombard And Story Partner To Revolutionize Creator Economy Via Bitcoin-Backed Infrastructure
- FBS AI Assistant Helps Traders Skip Market Noise And Focus On Strategy
Comments
No comment